Loading…

Loading grant details…

Active HORIZON European Commission

Deciphering non-genetic determinants and targetability of cancer cell plasticity.

€2M EUR

Funder European Commission
Recipient Organization Prinses Maxima Centrum Voor Kinderoncologie Bv
Country Netherlands
Start Date Jun 01, 2025
End Date May 31, 2030
Duration 1,825 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 101170012
Grant Description

IntroductionCancer cell plasticity, the ability of cancer cells to change their identity, enables tumors to adapt to hostile environments, aiding metastasis and resistance to treatments. Hence, plasticity is a major unsolved problem frustrating effective treatment. Unraveling the mechanisms underlying cancer cell plasticity is crucial to establish new avenues for cancer therapy.

In contrast to adult cancers, many pediatric tumors are driven by a single genetic alteration that fuels their aggressive nature through remarkable plasticity.

Despite their differences, pediatric cancers offer a unique platform to investigate cancer cell plasticity due to their genetically clear characteristics. I hypothesize that plasticity can be reversed to differentiate tumor cells and “mature cancer”.

GoalBuilding upon previous ERC-StG funding, we have successfully utilized organoid technology, single-cell genomics, and lineage tracing approaches to uncover the origins of various pediatric cancers.

Our findings revealed that these cancers exhibit robust yet pharmacologically reversible plasticity at the level of the epigenome. The goal of this proposal is to reverse cell state changes during tumorigenesis to “mature cancer”.

ApproachWe will I) apply advanced (spatial) single-cell transcriptomics and epigenomics approaches to a unique cohort of pediatric tumors and metastases to map out cell state changes during disease progression, II) utilize our unique pediatric cancer organoids to interrogate and target hierarchical trajectories with the aim to mature cancer, and III) screen the enhancer-ome to identify non-genetic determinants of cancer cell plasticity.

InnovationIntegrating these cutting-edge technologies on patient-derived tissues and organoids will uncover fundamental principles governing cancer cell plasticity.

The research will pioneer innovative methodologies and reveal strategies for identifying cancer maturation targets, advancing cancer therapy research

All Grantees

Prinses Maxima Centrum Voor Kinderoncologie Bv

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant